Opthea Announces Upcoming Presentations at the Retina World Congress 2024
May 01, 2024 07:30 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea to Present at the OIS Retina Innovation Summit at ARVO
April 25, 2024 09:00 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Appoints John Han, PharmD, as VP Medical Affairs
April 08, 2024 18:42 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
April 04, 2024 18:34 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Appoints Sujal Shah to the Board of Directors
April 03, 2024 17:39 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
March 19, 2024 06:00 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to...
Opthea to Participate in the Leerink Partners Global Biopharma Conference
March 05, 2024 17:08 ET
|
Opthea Limited
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly...
Opthea Reports Half-Year Financial Results and Business Updates
February 28, 2024 17:55 ET
|
Opthea Limited
Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025 Expanded U.S. leadership team with the appointments of Dr....
[Latest] Global Industrial Protective Clothing Market Size/Share Worth USD 20.63 Billion by 2032 at a 5.98% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
February 20, 2024 15:00 ET
|
Custom Market Insights
Austin, TX, USA, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Industrial Protective Clothing Market Size, Trends and Insights By Product (Heat...
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
February 19, 2024 18:25 ET
|
Opthea Limited
MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly...